Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs)

Toxicology and Applied Pharmacology

Volumn 273, Issue 1, 2013, Pages 100-109

  Li, Qing ^a,b   Guo, Dong ^b   Dong, Zhongqi ^a   Zhang, Wei ^a,b   Zhang, Lei ^c   Huang, Shiew Mei ^c   Polli, James E ^a   Shu, Yan ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cisplatin; Drug interaction; Multidrug and toxin extrusion protein; Nephrotoxicity; Ondansetron; Organic cation transporter

Indexed keywords

ALBUMIN; CISPLATIN; CREATININE; GLUCOSE; METFORMIN; MULTIPLE TOXIN AND EXTRUSION PROTEIN; ONDANSETRON; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; UREA NITROGEN BLOOD LEVEL; WILD TYPE;

5-HT(3); 5-HYDROXYTRYPTAMINE-3; AREA UNDER CURVE; AUC; BLOOD UREA NITROGEN; BUN; CISPLATIN; DRUG INTERACTION; HEK-293; HUMAN EMBRYONIC KIDNEY CELL; HUMAN MATE2 ISOFORMS (SPECIFIC IN THE KIDNEY); KIDNEY INJURY MOLECULAR-1 PROTEIN; KIM-1; LCN2; LIPOCALIN 2 GENE; MATE1/2; MATE2-K; MULTIDRUG AND TOXIN EXTRUSION 1/2; MULTIDRUG AND TOXIN EXTRUSION PROTEIN; NEPHROTOXICITY; OCT2; ONDANSETRON; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 2; SINGLE-NUCLEOTIDE POLYMORPHISM; SNP;

ANIMALS; CISPLATIN; HEK293 CELLS; HUMANS; KIDNEY; METFORMIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ONDANSETRON; ORGANIC CATION TRANSPORT PROTEINS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 84884722995     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.08.024     Document Type: Article

References (51)

1. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23:460-464.
2. Ayrton A., Morgan P. Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 2008, 38:676-708.
3. Chen L., Pawlikowski B., Schlessinger A., More S.S., Stryke D., Johns S.J., Portman M.A., Chen E., Ferrin T.E., Sali A., Giacomini K.M. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet. Genomics 2010, 20:687-699.
4. Ciarimboli G. Role of organic cation transporters in drug-induced toxicity. Expert Opin. Drug Metab. Toxicol. 2011, 7:159-174.
5. Dong Z., Ekins S., Polli J.E. Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol. Pharm. 2013, 10:1008-1019.
6. Filipski K.K., Loos W.J., Verweij J., Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 2008, 14:3875-3880.
7. Filipski K.K., Mathijssen R.H., Mikkelsen T.S., Schinkel A.H., Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 2009, 86:396-402.
8. Franke R.M., Kosloske A.M., Lancaster C.S., Filipski K.K., Hu C., Zolk O., Mathijssen R.H., Sparreboom A. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-d-glucosaminidase. Clin. Cancer Res. 2010, 16:4198-4206.
9. Giacomini K.M., Balimane P.V., Cho S.K., Eadon M., Edeki T., Hillgren K.M., Huang S.M., Sugiyama Y., Weitz D., Wen Y., Xia C.Q., Yee S.W., Zimdahl H., Niemi M. International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin. Pharmacol. Ther. 2013, 94:23-26.
10. Gorboulev V., Ulzheimer J.C., Akhoundova A., Ulzheimer-Teuber I., Karbach U., Quester S., Baumann C., Lang F., Busch A.E., Koepsell H. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997, 16:871-881.
11. Hesketh P.J., Van Belle S., Aapro M., Tattersall F.D., Naylor R.J., Hargreaves R., Carides A.D., Evans J.K., Horgan K.J. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer 2003, 39:1074-1080.
12. Hillgren K.M., Keppler D., Zur A.A., Giacomini K.M., Stieger B., Cass C.E., Zhang L. International Transporter Consortium. Emerging transporter of clinical importance: an update from the International Transporter Consortium. Clin. Pharmacol. Ther. 2013, 94:52-63.
13. Ito S., Kusuhara H., Yokochi M., Toyoshima J., Inoue K., Yuasa H., Sugiyama Y. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J. Pharmacol. Exp. Ther. 2012, 340:393-403.
14. Iwata K., Aizawa K., Kamitsu S., Jingami S., Fukunaga E., Yoshida M., Yoshimura M., Hamada A., Saito H. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin. Exp. Nephrol. 2012, 16:843-851.
15. Kalayda G.V., Wagner C.H., Jaehde U. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J. Inorg. Biochem. 2012, 116:1-10.
16. Kido Y., Matsson P., Giacomini K.M. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J. Med. Chem. 2011, 54:4548-4558.
17. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 2007, 24:1227-1251.
18. Komatsu T., Hiasa M., Miyaji T., Kanamoto T., Matsumoto T., Otsuka M., Moriyama Y., Omote H. Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter. Int. J. Biochem. Cell Biol. 2011, 43:913-918.
19. Kuhlmann M.K., Burkhardt G., Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol. Dial. Transplant. 1997, 12:2478-2480.
20. Li Q., Peng X., Yang H., Wang H., Shu Y. Deficiency of multidrug and toxin extrusion 1 enhances renal accumulation of paraquat and deteriorates kidney injury in mice. Mol. Pharm. 2011, 8(6):2476-2483. (Dec 5).
21. Lickteig A.J., Cheng X., Augustine L.M., Klaassen C.D., Cherrington N.J. Tissue distribution, ontogeny and induction of the transporters multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci. 2008, 83:59-64.
22. Masuda S., Terada T., Yonezawa A., Tanihara Y., Kishimoto K., Katsura T., Ogawa O., Inui K. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 2006, 17:2127-2135.
23. Matsushima S., Maeda K., Inoue K., Ohta K.Y., Yuasa H., Kondo T., Nakayama H., Horita S., Kusuhara H., Sugiyama Y. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab. Dispos. 2009, 37:555-559.
24. Molderings G.J., Bruss M., Bonisch H., Gothert M. Identification and pharmacological characterization of a specific agmatine transport system in human tumor cell lines. Ann. N. Y. Acad. Sci. 2003, 1009:75-81.
25. Morrissey K.M., Stocker S.L., Wittwer M.B., Xu L., Giacomini K.M. Renal transporters in drug development. Annu. Rev. Pharmacol. Toxicol. 2013, 53:503-529.
26. Motohashi H., Inui K. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013, 15:581-588.
27. Nakamura T., Yonezawa A., Hashimoto S., Katsura T., Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 2010, 80:1762-1767.
28. Nies A.T., Koepsell H., Damme K., Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol. 2011, 105-167.
29. Omote H., Hiasa M., Matsumoto T., Otsuka M., Moriyama Y. The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol. Sci. 2006, 27:587-593.
30. Otsuka M., Matsumoto T., Morimoto R., Arioka S., Omote H., Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17923-17928.
31. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73:994-1007.
32. Pabla N., Murphy R.F., Liu K., Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 2009, 296:F505-F511.
33. Roila F., Hesketh P.J., Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann. Oncol. 2006, 17:20-28.
34. Samardzic R., Jovanovic-Micic D., Beleslin D.B. 5HT-3 receptors: characteristics and therapeutic implications of a new subtype of 5-hydroxytryptamine receptors. Srp. Arh. Celok. Lek. 1994, 122:82-85.
35. Sastry J., Kellie S.J. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr. Hematol. Oncol. 2005, 22:441-445.
36. Sharma V., McNeill J.H. To scale or not to scale: the principles of dose extrapolation. Br. J. Pharmacol. 2009, 157:907-921.
37. Shu Y., Sheardown S.A., Brown C., Owen R.P., Zhang S., Castro R.A., Ianculescu A.G., Yue L., Lo J.C., Burchard E.G., Brett C.M., Giacomini K.M. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 2007, 117:1422-1431.
38. Shu Y., Brown C., Castro R.A., Shi R.J., Lin E.T., Owen R.P., Sheardown S.A., Yue L., Burchard E.G., Brett C.M., Giacomini K.M. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 2008, 83:273-280.
39. Skvortsov A.N., Zatulovskii E.A., Puchkova L.V. Structure-functional organization of eukaryotic high-affinity copper importer CTR1 determines its ability to transport copper, silver and cisplatin. Mol. Biol. (Mosk) 2012, 46:335-347.
40. Stout P.R., Bynum N.D., Lewallen C.M., Mitchell J.M., Baylor M.R., Ropero-Miller J.D. A comparison of the validity of gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry analysis of urine samples II: amphetamine, methamphetamine, (+/-)-3,4-methylenedioxyamphetamine, (+/-)-3,4-methylenedioxymethamphetamine, (+/-)-3,4-methylenedioxyethylamphetamine, phencyclidine, and (+/-)-11-nor-9-carboxy-delta(9)-tetrahydrocannabinol. J. Anal. Toxicol. 2010, 34:430-443.
41. Tsuda M., Terada T., Mizuno T., Katsura T., Shimakura J., Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol. 2009, 75:1280-1286.
42. Tzvetkov M.V., Saadatmand A.R., Bokelmann K., Meineke I., Kaiser R., Brockmoller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 2012, 12:22-29.
43. Wang D.S., Jonker J.W., Kato Y., Kusuhara H., Schinkel A.H., Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 2002, 302:510-515.
44. Wang E.J., Snyder R.D., Fielden M.R., Smith R.J., Gu Y.Z. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 2008, 246:91-100.
45. Wang Z.J., Yin O.Q., Tomlinson B., Chow M.S. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics 2008, 18:637-645.
46. Wasilewska A., Zoch-Zwierz W., Taranta-Janusz K., Michaluk-Skutnik J. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity?. Pediatr. Nephrol. 2010, 25:889-897.
47. Wittwer M.B., Zur A.A., Khuri N., Kido Y., Kosaka A., Zhang X., Morrissey K.M., Sali A., Huang Y., Giacomini K.M. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J. Med. Chem. 2013, 56(3):781-795. (Feb 14).
48. Yokoo S., Yonezawa A., Masuda S., Fukatsu A., Katsura T., Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 2007, 74:477-487.
49. Yonezawa A. Platinum agent-induced nephrotoxicity via organic cation transport system. Yakugaku Zasshi 2012, 132:1281-1285.
50. Zhang J., Zhou W. Ameliorative effects of SLC22A2 gene polymorphism 808G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem. Toxicol. 2012, 50:2289-2293.
51. Zhang S., Lovejoy K.S., Shima J.E., Lagpacan L.L., Shu Y., Lapuk A., Chen Y., Komori T., Gray J.W., Chen X., Lippard S.J., Giacomini K.M. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006, 66:8847-8857.